Loading clinical trials...
Loading clinical trials...
Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age
Conditions
Interventions
FluLaval™ Quadrivalent
Fluzone® Quadrivalent
Locations
66
United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Dothan, Alabama, United States
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
Jonesboro, Arkansas, United States
GSK Investigational Site
Anaheim, California, United States
GSK Investigational Site
Chino, California, United States
Start Date
October 1, 2014
Primary Completion Date
March 16, 2015
Completion Date
June 23, 2015
Last Updated
September 7, 2018
NCT01386424
NCT07169318
NCT07291635
NCT06599658
NCT06094010
NCT06753474
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions